tiprankstipranks
Wuxi Biologics (Cayman) Inc. (WXIBF)
OTHER OTC:WXIBF
Holding WXIBF?
Track your performance easily

Wuxi Biologics (Cayman) (WXIBF) Income Statement

118 Followers

Wuxi Biologics (Cayman) Income Statement

Last quarter (Q2 2022), Wuxi Biologics (Cayman)'s total revenue was ¥7.21B, an increase of Infinity% from the same quarter last year. In Q2, Wuxi Biologics (Cayman)'s net income was ¥―. See Wuxi Biologics (Cayman)’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
¥ 11.61B¥ 10.29B¥ 5.61B¥ 3.98B¥ 2.53B¥ 1.62B
Cost of Revenue
-¥ 5.46B¥ 3.08B¥ 2.32B¥ 1.52B¥ 958.27M
Gross Profit
-¥ 4.83B¥ 2.53B¥ 1.66B¥ 1.02B¥ 660.56M
Operating Expense
-¥ 1.36B¥ 771.43M¥ 601.77M¥ 323.62M¥ 210.17M
Operating Income
-¥ 3.46B¥ 1.76B¥ 1.06B¥ 694.14M¥ 450.38M
Net Non Operating Interest Income Expense
-¥ 18.84M¥ 38.13M¥ 44.25M¥ 78.39M¥ -26.95M
Other Income Expense
------
Pretax Income
-¥ 3.99B¥ 1.97B¥ 1.13B¥ 737.72M¥ 303.69M
Tax Provision
-¥ 484.54M¥ 273.07M¥ 116.30M¥ 107.26M¥ 51.06M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-¥ 3.39B¥ 1.69B¥ 1.01B¥ 630.59M¥ 252.63M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-¥ 6.83B¥ 3.85B¥ 2.93B¥ 1.84B¥ 1.17B
Net Income From Continuing And Discontinued Operation
-¥ 3.39B¥ 1.69B¥ 1.01B¥ 630.59M¥ 252.63M
Normalized Income
-¥ 3.24B¥ 1.47B¥ 981.18M¥ 749.19M¥ 271.77M
Interest Expense
-¥ 39.19M¥ 42.73M¥ 19.61M¥ 0.00¥ 35.69M
EBIT
-¥ 4.03B¥ 2.01B¥ 1.15B¥ 737.72M¥ 339.38M
EBITDA
-¥ 4.51B¥ 2.31B¥ 1.37B¥ 881.49M¥ 426.86M
Currency in CNY

Wuxi Biologics (Cayman) Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis